Urology

Hal & Mary: Another Happy HIFU Story

Posted on HIFU Prostate Services 5/27/2017 If you ask Hal Plimpton, he will tell you that he is a semi-retired, international logistics consultant who has owned and operated his own business for many years. If his wife, Mary, happens to hear him say he is “semi” retired, she will laugh and probably roll her eyes. “He was supposed to retire 15 years ago, but he’s still working,” said Mary. However, one thing that Hal and Mary can agree on is that they made a good treatment decision several years ago when Hal was diagnosed with prostate cancer. “I could tell that he felt really good about HIFU (high intensity focused ultrasound). He had confidence in the technology that it was going to work. I was a [...]

2017-12-13T13:37:20+00:00 May 31st, 2017|

New blood test better at predicting prostate cancer risk than PSA

A new blood test known as IsoPSA detects prostate cancer more precisely than current tests in two crucial measures -- distinguishing cancer from benign conditions, and identifying patients with high-risk disease. By identifying molecular changes in the PSA protein, the findings of this study suggest that once validated, use of IsoPSA may reduce the need for biopsy, and may lower the likelihood of overdetection and overtreatment of nonlethal prostate cancer. A team of researchers from Cleveland Clinic, Louis Stokes Cleveland VA Medical Center, Kaiser Permanente Northwest, and other clinical sites have demonstrated that a new blood test known as IsoPSA detects prostate cancer more precisely than current tests in two crucial measures -- distinguishing cancer from benign conditions, and identifying patients with high-risk disease. By [...]

2017-12-13T13:37:20+00:00 May 16th, 2017|

Common Prostate Cancer Therapy May Trigger Dementia

A new analysis of patients who have undergone treatment for prostate cancer shows a connection between androgen deprivation therapy (ADT) -- a testosterone-lowering therapy and a common treatment for the disease -- and dementia, according to researchers from the Perelman School of Medicine at the University of Pennsylvania. Their previous studies have shown men who undergo ADT may be at an increased risk of dementia, including Alzheimer's disease, compared to men who were not treated with the therapy. This new analysis -- the largest of its kind ever performed on this topic -- shows that all existing studies taken together support the link to dementia and show a possible link to Alzheimer's. The findings are published this week in Prostate Cancer and Prostatic Diseases. "Since [...]

2017-12-13T13:37:20+00:00 April 4th, 2017|

Study Reveals Quality of Life Concerns Paramount in Prostate Cancer Treatment Options

For many men newly diagnosed with early-stage prostate cancer, concerns about potential quality-of-life issues often guide treatment decisions. A new study led by UNC Lineberger Comprehensive Cancer Center researchers identifies distinct patterns of side effects that patients could use to guide their choices. In the Journal of the American Medical Association, the study examines quality-of-life outcomes for the treatment choices most patients will face. Those choices include active surveillance, radical prostatectomy, external beam radiation treatment, and brachytherapy, a treatment that involves inserting radioactive seeds into the prostate. "Patients diagnosed with early-stage prostate cancer -- and that's the vast majority of patients with this disease -- face many treatment options that are thought to be similarly efficacious," said Ronald C. Chen, MD, MPH, UNC Lineberger member [...]

2017-12-13T13:37:20+00:00 March 27th, 2017|

Study reveals genetic connection to aggressive prostate cancer

An international study published in the Journal of the National Cancer Institute has identified a genetic connection to the aggressive form of prostate cancer. The study showed a threefold increase in the risk of aggressive prostate cancer for men with the genetic mutation. The frequency of the gene variants varied from 6 to 14% of the population of men with prostate cancer. Much like the association between BRCA gene mutation and the risk for breast cancer in women changed the approach to treatment/ prevention, the identification of the Kallikrein 6 gene region may change the course of prostate cancer care through a blood test developed by the Lunenfeld-Tanenbaum Research Institute. The study was led by Dr. Alexandre Zlotta, Director of Uro-Oncology at Mount Sinai Hospital, [...]

2017-12-13T13:37:20+00:00 March 21st, 2017|

Dr. Michael Lazar Offers Free HIFU Presentation Online

Dr. Michael Lazar of California HIFU recently gave a presentation in Santa Rosa discussing the benefits of high-intensity focused ultrasound for prostate cancer and now offers the presentation online. A public presentation recently held in Santa Rosa for a group gathered to learn more about high-intensity focused ultrasound (HIFU) provided an overview of how this exciting new prostate cancer treatment works, and included comparisons to other treatment options, as well as HIFU patient outcomes. The event also offered people a chance to meet Dr. Lazar who is a four-time board certified urologist and prostate cancer specialist providing HIFU to patients in California. It also gave attendees a chance to learn more prostate cancer and to ask important questions. During the presentation, Dr. Lazar discussed how [...]

2017-12-13T13:37:21+00:00 March 6th, 2017|